Targeting immune suppression in head and neck cancer using specialized drug delivery
Stimuli-responsive Delivery of Ectonucleotidase Inhibitors to Reprogram Immunometabolism in Head and Neck Cancer
This study is testing a new way to help your immune system fight head and neck cancer by using tiny particles that release special medicines when exposed to light, aiming to make treatments more effective and reduce side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project ID | NIH-10589885 on NIH RePORTER |
What this research studies
This research focuses on overcoming the immune suppression that often occurs in head and neck cancer due to the tumor microenvironment. It utilizes nanoparticles that can release specific inhibitors in response to stimuli, such as light, to enhance the body's immune response against cancer cells. By delivering these inhibitors selectively to the tumor site, the goal is to improve the effectiveness of cancer therapies while minimizing side effects. Patients may benefit from a more targeted approach to treatment that could enhance their immune system's ability to fight cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with head and neck cancer who are undergoing or considering immunotherapy.
Not a fit: Patients with non-malignant conditions or those who do not have head and neck cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for head and neck cancer by enhancing the immune response without causing significant toxicity.
How similar studies have performed: Previous research has shown promise in using targeted drug delivery systems to enhance cancer immunotherapy, indicating that this approach may be effective.
Where this research is happening
Winston-Salem, United States
- Wake Forest University Health Sciences — Winston-Salem, United States (Active)
Researchers
- Principal investigator: Ming, Xin — Wake Forest University Health Sciences
- Study coordinator: Ming, Xin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.